Black–White Mortality From HIV in the United States Before and After Introduction of Highly Active Antiretroviral Therapy in 1996
Robert S. Levine, MD,
Nathaniel C. Briggs, MD, MSc,
Barbara S. Kilbourne, PhD,
William D. King, MD, JD,
Yvonne Fry-Johnson, MD,
Peter T. Baltrus, PhD,
Baqar A. Husaini, PhD and
George S. Rust, MD, MPH
Robert S. Levine and Nathaniel C. Briggs are with the Department of Family and Community Medicine, Meharry Medical College, Nashville, Tenn. Barbara S. Kilbourne is with the Department of Sociology, Tennessee State University, Nashville. William D. King is with the Department of Internal Medicine, University of California, Los Angeles. Yvonne Fry-Johnson, Peter T. Baltrus, and George S. Rust are with the National Center for Primary Care, Morehouse School of Medicine, Atlanta, Ga. Baqar A. Husaini is with the Center for Health Research, Tennessee State University, Nashville.
FIGURE 1——Black-to-White HIV-related mortality rate ratios among (a) men aged 25 to 74 years and (b) women aged 25 to 64 years: United States, 1990 to 2002.
Note. Reporting is restricted to 10-year age groups for which reliable data for all years were available. The horizontal line indicates the introduction of highly active antiretroviral therapy.
FIGURE 2——Black:White HIV mortality among men aged 25 years and older in the United States and in US counties with a mortality rate ratio (MRR) of 2.0 or less, by (a) MRRs and (b) race-specific, age-adjusted mortality rates: 1990–2002.
Note. In counties with at least 20 deaths among Blacks from HIV/AIDS.
FIGURE 3——Black:White HIV mortality among men aged 25 years and older in the United States and in US counties with a mortality rate ratio (MRR) of 15.0 or higher, by (a) MRRs and (b) race-specific, age-adjusted mortality rates: 1990–2002.
Note. In counties with at least 20 deaths among Blacks from HIV/AIDS.
